08:19 AM EDT, 07/29/2024 (MT Newswires) -- AstraZeneca ( AZN ) said Monday that Calquence with venetoclax showed a "statistically significant and clinically meaningful" improvement in progression-free survival compared to chemoimmunotherapy in previously untreated adult patients with chronic lymphocytic leukemia in a phase 3 trial interim analysis.

The safety and tolerability were consistent with the known safety profile of each medicine and no new safety signals were identified, with low rates of cardiac toxicity observed, the company said.

AstraZeneca's ( AZN ) shares were up more than 2% during recent pre-market activity on Monday.

Price: 80.09, Change: +1.96, Percent Change: +2.51